Abstract
KCa3.1 protein is part of a heterotetrameric voltage-independent potassium channel, the activity of which depends on the intracellular calcium binding to calmodulin. KCa3.1 is immensely significant in regulating immune responses and primarily expressed in cells of hematopoietic lineage. It is one of the attractive pharmacological targets that are known to inhibit neuroinflammation. KCa3.1 blockers mediate neuroprotection through multiple mechanisms, such as by targeting microglia-mediated neuronal killing. KCa3.1 modulators may provide alternative treatment options for neurological disorders like ischemic stroke, Alzheimer disease, glioblastoma multiforme, multiple sclerosis and spinal cord injury. This review is an attempt to draw attention towards KCa3.1 channel, which was never exploited to its full potential as a viable therapeutic candidate against various neurological disorders.
Keywords: Alzheimer disease, glioblastoma multiforme, ischemic stroke, KCa3.1, KCNN4, multiple sclerosis.
CNS & Neurological Disorders - Drug Targets
Title:Role of KCa3.1 Channels in CNS Diseases: A Concise Review
Volume: 15 Issue: 10
Author(s): Sinoy Sugunan, Sreekala S. Nampoothiri, Tanya Garg and Rajanikant G. Krishnamurthy
Affiliation:
Keywords: Alzheimer disease, glioblastoma multiforme, ischemic stroke, KCa3.1, KCNN4, multiple sclerosis.
Abstract: KCa3.1 protein is part of a heterotetrameric voltage-independent potassium channel, the activity of which depends on the intracellular calcium binding to calmodulin. KCa3.1 is immensely significant in regulating immune responses and primarily expressed in cells of hematopoietic lineage. It is one of the attractive pharmacological targets that are known to inhibit neuroinflammation. KCa3.1 blockers mediate neuroprotection through multiple mechanisms, such as by targeting microglia-mediated neuronal killing. KCa3.1 modulators may provide alternative treatment options for neurological disorders like ischemic stroke, Alzheimer disease, glioblastoma multiforme, multiple sclerosis and spinal cord injury. This review is an attempt to draw attention towards KCa3.1 channel, which was never exploited to its full potential as a viable therapeutic candidate against various neurological disorders.
Export Options
About this article
Cite this article as:
Sugunan Sinoy, Nampoothiri S. Sreekala, Garg Tanya and Krishnamurthy G. Rajanikant, Role of KCa3.1 Channels in CNS Diseases: A Concise Review, CNS & Neurological Disorders - Drug Targets 2016; 15 (10) . https://dx.doi.org/10.2174/1871527315666160822111913
DOI https://dx.doi.org/10.2174/1871527315666160822111913 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurokinin Peptides and Neurokinin Receptors as Potential Therapeutic Intervention Targets of Basal Ganglia in the Prevention and Treatment of Parkinsons Disease
Current Drug Targets Steroid Biosynthesis Inhibitors in the Therapy of Hypercortisolism: Theory and Practice
Current Medicinal Chemistry New Approaches for the Treatment of Pain: The GDNF Family of Neurotrophic Growth Factors
Current Topics in Medicinal Chemistry New Insights into Serotonin 5-HT4 Receptors : A Novel Therapeutic Target for Alzheimers Disease?
Current Alzheimer Research Silica Sulfuric Acid (SSA): An Efficient and Heterogeneous Catalyst for Organic Transformations
Mini-Reviews in Organic Chemistry Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Commentary (Complement-Initiated Neuroinflammation and Its Role in Early Stage Alzheimers Disease)
Current Alzheimer Research Editorial (How Natural is it for Nature to Help with Major Depressive Disorder?)
CNS & Neurological Disorders - Drug Targets Mini-Review: Spinocerebellar Ataxias: An Update of SCA Genes
Recent Patents on DNA & Gene Sequences Obstructive Sleep Apnea and Autoimmune Rheumatic Disease: Is there Any Link?
Inflammation & Allergy - Drug Targets (Discontinued) Neuropharmacology of the Interoceptive Stimulus Properties of Nicotine
Current Drug Abuse Reviews C-1073 (Mifepristone) in the Adjunctive Treatment of Alzheimers Disease
Current Alzheimer Research Pharmacological Approaches of Binge Drinking
Current Pharmaceutical Design Neuroanatomical and Neurophysiological Abnormalities in the Neural Correlates of Face Processing in Schizophrenia
Current Psychiatry Reviews Gabapentin-Mediated Effects on Voltage- and Ligand-Gated Currents
Current Neuropharmacology Is Cdc25 a Druggable Target?
Anti-Cancer Agents in Medicinal Chemistry Natural Antioxidants in Wheat Sprout Extracts
Current Organic Chemistry Endoplasmic Reticulum Dysfunction in Brain Pathology: Critical Role of Protein Synthesis
Current Neurovascular Research Meet Our Editorial Board Member
Current Alzheimer Research The Involvement of Lysosomes in Myocardial Aging and Disease
Current Cardiology Reviews